SCHEMBL6741726

SCHEMBL6741726

CC1=CCCC(C)OCC2OC(=O)C(CN3CCOCC3)C2CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
TAS2R46 P59540 10/20 0.37
HSP90AA1 P07900 1/20 0.33
CCR6 P51684 1/20 0.33
MAPT P10636 1/20 0.32
MEN1 O00255 2/20 0.32
MITF O75030 1/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TERT O14746 1/20 0.32
PKM P14618 1/20 0.32
TAS2R31 P59538 2/20 0.31
TAS2R10 Q9NYW0 2/20 0.31
ADRA2A P08913 1/20 0.30
DRD2 P14416 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
DRD1 P21728 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6741385 0.92 KMT2A (0.39) KMT2ATAS2R46MEN1MITFPOLB
SCHEMBL6745284 0.91 KMT2A (0.40) KMT2ATAS2R46MEN1MITFPOLB
SCHEMBL6739764 0.90 TAS2R46 (0.37) KMT2ATAS2R46MEN1MITFPOLB
SCHEMBL6741650 0.80 TAS2R46 (0.41) KMT2ATAS2R46MEN1RECQLTDP1
SCHEMBL6742416 0.79 TAS2R46 (0.36) KMT2ATAS2R46MEN1MITFTAS2R31
SCHEMBL6744280 0.78 TAS2R46 (0.39) KMT2ATAS2R46MEN1RECQLTDP1
SCHEMBL6739772 0.75 TAS2R46 (0.39) TAS2R46TAS2R31TAS2R10
SCHEMBL6741730 0.73 PKM (0.51) KMT2AMAPTMEN1PKMLMNA
SCHEMBL6741724 0.73 PKM (0.51) KMT2AMAPTMEN1PKMLMNA
SCHEMBL6741389 0.64 PKM (0.53) KMT2ATAS2R46MAPTMEN1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229936-A1 Treatment of hepatitis C virus infection with sesquiterpene lactones HSIEH HSING-PANG (TW) 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229936-A1 Treatment of hepatitis C virus infection with sesquiterpene lactones HAVCR2, HCCS, ZC3HAV1 KMT2A 4010/4885TAS2R46 3891/4885HSP90AA1 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.